

STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN REMOGLIFLOZIN ETABONATE


PRONUNCIATION re moe" gli floe' zin

THERAPEUTIC CLAIM Treatment of type 2 diabetes

CHEMICAL NAMES

1.  $\beta$ -D-Glucopyranoside, 5-methyl-4-[[4-(1-methylethoxy)phenyl]methyl]-1-(1-methylethyl)-1*H*-pyrazol-3-yl, 6-(ethyl carbonate)
2. 5-methyl-4-[4-(1-methylethoxy)benzyl]-1-(1-methylethyl)-1*H*-pyrazol-3-yl 6-*O*-(ethoxycarbonyl)- $\beta$ -D-glucopyranoside

STRUCTURAL FORMULA



MOLECULAR FORMULA  $C_{26}H_{38}N_2O_9$

MOLECULAR WEIGHT 522.6

CODE GSK 189075A

TRADEMARK None as yet

MANUFACTURER GlaxoSmithKline

CAS REGISTRY NUMBER 442201-24-3